Clinical Report: Reliability of Metabolomics-Based Chemical Grouping

Overview

The MATCHING ring trial found that partners with metabolomics datasets passing quality control consistently assigned eight test substances to three effect groups despite methodological differences. Part 2 addresses a remaining question: whether the metabolic responses underlying those groups are consistent across partners and interpretable in relation to androgen receptor activity, peroxisome proliferation, and anaemia. The supplied article excerpt describes an AOP-informed approach for interpreting metabolite changes but does not provide Part 2’s results.

Background

Grouping chemicals and applying read-across can support chemical safety assessment while limiting animal testing, but grouping hypotheses may be rejected when they rely on structural similarity without evidence of shared biological effects. Metabolomics measures endogenous small-molecule changes following exposure and may provide biological-response evidence relevant to chemical categorisation. The earlier MATCHING ring trial established reproducibility of in vivo metabolomics-based grouping, but did not assess consistency or toxicological interpretation of the molecular responses within groups. The article introduces metabolomic associative events (mAEs), linked to key events in an Adverse Outcome Pathway, as a framework for interpreting those responses.

Data Highlights

Key Findings

• The earlier MATCHING ring trial used plasma from rats exposed to eight substances over 28 days at high or low dose levels.
• Ring-trial partners were blinded to substance identities; partners whose metabolomics datasets passed quality control assigned the substances to three effect groups with high consistency.
• Grouping consistency was observed despite methodological differences among partners, while the study also identified data quality assessment as necessary before grouping.
• The earlier trial did not determine whether molecular responses underlying the groups were consistent across partners or whether discriminatory metabolites could be interpreted using toxicological knowledge of AR activity, PP, and anaemia.
• The article describes mAEs as measurable biological processes associated with AOP key events; they need not be causal but can indicate a toxicological effect.
• The proposed interpretation strategy maps metabolites and lipids to mAEs using biochemical and toxicometabolomics knowledge, then evaluates which mAEs are supported by exposure data; the supplied excerpt does not report the Part 2 findings.

Clinical Implications

The source frames toxicological interpretation of metabolomics as relevant to the strength of evidence for regulatory chemical grouping: statistical analysis alone is described as a lower evidence level than interpretation that supports a mechanistic rationale. It presents mAE mapping as an approach for interpreting metabolic responses, but the supplied excerpt does not establish its performance or provide a basis for specific regulatory decisions.

Conclusion

The earlier MATCHING trial supports reproducible in vivo metabolomics-based grouping when data pass quality control, while consistency and interpretation of within-group metabolic effects remain the focus of Part 2. The provided material outlines an AOP-informed mAE framework but contains no results from that assessment.

Related Resources & Content

1. Viant et al., Archives of Toxicology, 2024 — Establishing the Consistency of In Vivo Metabolomics for Chemical Classification: A Move Towards Optimal Practices
2. OECD, 2026 — Guidance on Grouping of Chemicals, Third Edition
3. ECHA, n.d. — Grouping of substances and read-across
4. OECD, 2023 — OECD Omics Reporting Framework (OORF): Guidance on reporting elements for the regulatory use of omics data from laboratory-based toxicology studies
5. Archives of Toxicology — Developing a Framework for Chemical Classification: Transitioning from Toxicogenomics Data to Cumulative Assessment Groups
6. Archives of Toxicology — Application of In Vivo Metabolomics to Facilitate Read-Across for UVCB Compounds in Compliance with REACH Regulations
7. Archives of Toxicology — Variation of Clinical Chemistry Parameters Across Laboratories in Seven-Day Acute Hydrazine Toxicity Studies Using Sprague-Dawley Rats
8. Guidance on Grouping of Chemicals, Third Edition | OECD
9. Grouping of substances and read-across - ECHA
10. Integrated Approaches to Testing and Assessment (IATA) | OECD
11. OECD Omics Reporting Framework (OORF)
12. Guidance on Grouping of Chemicals, Third Edition | OECD
13. Grouping of substances and read-across - ECHA
14. Working with Groups - ECHA
15. Integrated Approaches to Testing and Assessment (IATA) | OECD
16. OECD Omics Reporting Framework (OORF): Guidance on reporting elements for the regulatory use of omics data from laboratory-based toxicology studies (EN)
17. Omics technologies in chemical testing | OECD
18. EUR-Lex - 52026SC0144 - EN - EUR-Lex
19. Analytical methods - Harmonised templates | OECD
20. Publications on testing and assessment of chemicals | OECD
21. Quantitative Structure-Activity Relationships Project | OECD